CUE vs STE · rev $9.3M vs P/E 25, rev $5.46B
Cue Biopharma (CUE) versus STERIS plc (STE) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
STERIS plc (STE) is a medical devices company listed on NYSE.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported STE revenue for 2025-03-31 was $5.46B. Net income was $616.1M. Revenue was up 284.6% from 2024-03-31 to 2025-03-31. STE currently screens at market cap $19.43B and trailing P/E 25.1.
CUE currently screens at market cap $59.5M. STE currently screens at market cap $19.43B and trailing P/E 25.1.
Not investment advice. Open the CUE and STE stock pages for the full models.
Not investment advice.